Translational cancer research最新文献

{"title":"Emodin reverses sorafenib resistance in hepatocellular carcinoma by inhibiting epithelial-mesenchymal transition via the Akt signaling pathway.","authors":"Qingqing Wang, Jie Zhang","doi":"10.21037/tcr-24-1260","DOIUrl":"10.21037/tcr-24-1260","url":null,"abstract":"<p><strong>Background: </strong>Sorafenib resistance poses a significant challenge in the management of advanced hepatocellular carcinoma (HCC). Therefore, understanding the mechanisms behind sorafenib resistance is crucial for reversing resistance and enhancing the therapeutic effect of this anti-cancer drug. In this study, the molecular mechanisms underlying the ability of emodin to reverse sorafenib resistance were examined in sorafenib-resistant Huh7 (Huh7SR) cells.</p><p><strong>Methods: </strong>In this study, we successfully established a Huh7SR cell line that was subsequently divided into four treatment groups: control, sorafenib, emodin, and a combination of sorafenib and emodin. The cell viability, migration, invasion, colony formation capacity, and apoptosis of cells were assessed using the Cell Counting Kit-8 (CCK-8), transwell, colony formation, flow cytometry, and Hoechst staining assays, respectively. Using western blot analysis, we investigated proteins associated with apoptosis, epithelial-mesenchymal transition (EMT), and AKT signaling to explore the molecular mechanisms of emodin-dependent sorafenib resistance reversal.</p><p><strong>Results: </strong>Notably, sorafenib and emodin combination treatment exhibited a synergistic effect, enhancing chemosensitivity and apoptosis while inhibiting proliferation, colony formation, migration, and invasion. Additionally, western blotting showed that emodin significantly enhanced sorafenib's ability to reverse EMT, induce apoptosis, and inhibit AKT signaling in Huh7SR cells.</p><p><strong>Conclusions: </strong>Our study demonstrated that emodin effectively enhances sorafenib sensitivity, promotes apoptosis, and reverses EMT in Huh7SR cells through inhibition of the Akt signaling pathway. A limitation of this study is the exclusive use of a single cell line. Overall, emodin can enhance sorafenib's efficacy as an adjuvant therapy in the treatment of HCC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"286-295"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: miR-137 represses migration and cell motility by targeting COX-2 in non-small cell lung cancer.","authors":"","doi":"10.21037/tcr-2024b-10","DOIUrl":"10.21037/tcr-2024b-10","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/tcr-22-2177.].</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"656-657"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating restriction from interstitial lung disease (ILD) with stereotactic ablative radiotherapy (SABR) in early-stage non-small cell lung cancer: soaring beyond the current treatment paradigm.","authors":"Ari A Kassardjian, Jyoti Malhotra, Percy Lee","doi":"10.21037/tcr-24-1813","DOIUrl":"10.21037/tcr-24-1813","url":null,"abstract":"","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"11-15"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On the precipice of a new generation of biomarkers for immunotherapy in small cell lung cancer.","authors":"Peiran Sun, Stephanie Snow","doi":"10.21037/tcr-24-1711","DOIUrl":"10.21037/tcr-24-1711","url":null,"abstract":"","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"24-28"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the quality of vulvar cancer-related videos on YouTube.","authors":"Ting Xu, Hui Zhao","doi":"10.21037/tcr-24-1411","DOIUrl":"10.21037/tcr-24-1411","url":null,"abstract":"<p><strong>Background: </strong>Vulvar cancer is a relatively rare malignant tumor that receives less attention than other gynecological malignancies. Short-video apps are playing an important role in promoting health. This study evaluated the quality of videos about vulvar cancer on YouTube with the aim of making facts-based recommendations and promoting public health engagement.</p><p><strong>Methods: </strong>On May 15, 2024, the term \"vulvar cancer\" was searched on YouTube, and the top 100 videos identified in the search were chosen for our research. We evaluated the completeness of each video using six dimensions. The video quality was evaluated using the DISCERN instrument (Quality Criteria for Consumer Health Information), the <i>Journal of the American Medical Association</i> (<i>JAMA</i>) benchmark criteria, the Patient Education Materials Assessment Tool (PEMAT), and the Global Quality Scale (GQS). Correlations between video data, DISCERN, <i>JAMA</i>, PEMAT, and GQS scores were analyzed.</p><p><strong>Results: </strong>Among the 65 videos that were included in this study, the majority (64.6%) were posted by educational and training institutes. The quality of the videos submitted by physicians was comparatively good, as indicated by the GQS scores (P=0.045). The relationships between the DISCERN categorization score and duration (P<0.001), views per day (P=0.02), likes per day (P<0.001), comments per day (P=0.03), PEMAT actionability (P<0.001), and GQS scores (P<0.001) were statistically significant. Additionally, there was a strong positive correlation between the GQS score and video length.</p><p><strong>Conclusions: </strong>The quality of videos about vulvar cancer on YouTube is unsatisfactory. However, several measures can be adopted in the future to make YouTube a more practical tool for promoting the prevention and cure of vulvar cancer.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"102-111"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between survival outcomes in patients with colorectal liver metastasis undergoing hepatectomy and significance of fibrotic markers for liver injury assessment.","authors":"Atsushi Nanashima, Masahide Hiyoshi, Naoya Imamura, Takeomi Hamada, Yuki Tsuchimochi, Ikko Shimizu, Takahiro Ochiai, Akiko Ichihara, Kiyoaki Hamada, Nobuhiko Ichiki, Kengo Kai, Kazuhiro Higuchi","doi":"10.21037/tcr-24-1138","DOIUrl":"10.21037/tcr-24-1138","url":null,"abstract":"<p><strong>Background: </strong>Progression of chronic liver dysfunction influenced by long-term chemotherapy or repeated hepatectomy might be related to patient overall survival as well as tumor factors in colorectal liver metastasis (CLM) patients. Our aim of this study was to clarify the relationship between fibrotic liver damage and malignant behaviors of CLM malignancy or its long-term survivals by the retrospective cohort study.</p><p><strong>Methods: </strong>We examined the relationship between tumor-related factors or six liver fibrosis-associated parameters, including platelet count, hyaluronic acid (HA), mac-2 binding protein glycosylation isomer (M2BPGi), type IV collagen 7S (T4C7), aspartate aminotransferase-to-platelet ratio index (APRI), The fibrosis-4 (Fib-4) index, and clinicopathological parameters, surgical records, and postoperative patient survival in the 45 consecutive patients with CLM who underwent radical hepatectomy.</p><p><strong>Results: </strong>Fibrotic parameters were platelet count of 23.0±8.5 ×10⁴/µL, HA level of 68.9±82.3 ng/mL, M2BPGi of 0.87±0.48 ng/mL, and type IV collagen level of 5.74±3.76 ng/mL. Platelet count was significantly correlated with HA level (P<0.05) and tended to be correlated with M2BPGi levels (P=0.056). HA level was significantly associated with albumin level (P<0.05). Overall survival in this series showed five-year overall survivors after hepatectomy in 44 patients (98%), but cancer-related deaths were observed in only one patient. Patients with higher grades and increased bilirubin levels demonstrated significantly lower cancer-free survival (P<0.05), but fibrotic parameters were not associated with prognostic factors.</p><p><strong>Conclusions: </strong>Fibrotic markers indicating chemotherapy or repeated surgical liver injury were not significant predictive factors reflecting cancer malignant behaviors or patient overall survival, contrary to our hypothesis. The current overall survival status using various modalities for cancer recurrence is satisfactory under our present perioperative management.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"461-472"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing a prognostic scoring system and exploring prognostic value of examined lymph node numbers for stage I non-small cell lung cancer: a retrospective study of Surveillance, Epidemiology, and End Results (SEER) database and a Chinese cohort.","authors":"Siyuan Wang, Xin Yin, Lingyun Wu, Hao Yu, Zhongjie Lu, Feng Zhao, Danfang Yan, Senxiang Yan","doi":"10.21037/tcr-24-1474","DOIUrl":"10.21037/tcr-24-1474","url":null,"abstract":"<p><strong>Background: </strong>There is currently no recognized assessment system to predict disease outcomes for stage I non-small cell lung cancer (NSCLC). This research aimed to develop a prognostic scoring system for predicting 5-year overall survival (OS) of individuals with stage I NSCLC following definitive therapeutic intervention. Additionally, the optimal number of examined lymph nodes (ELNs) count for tumors no larger than 30 mm was determined.</p><p><strong>Methods: </strong>Patients (n=22,617) diagnosed with stage I NSCLC from 2007 to 2015 who underwent definitive treatment (pulmonary lobectomy, pulmonary sublobectomy, or radiotherapy) were identified from the Surveillance, Epidemiology, and End Results (SEER) database. There were 400 Chinese patients with stage I NSCLC diagnosed in 2017 enrolled for external validation. The nomogram was constructed based on gradient boosting machine. The optimal ELNs in patients with tumors ≤30 mm and node-negative undergoing pulmonary lobectomy or pulmonary sublobectomy were determined using log-rank test and validated by multivariable analysis.</p><p><strong>Results: </strong>Age at diagnosis, histology, differentiated grade, tumor staging, number of ELNs, and definitive treatment pattern were recognized as important factors for 5-year OS. The prognostic scoring system exhibited superior discrimination accuracy, calibration ability, and net clinical benefit compared to the tumor, node, metastasis (TNM) staging system. For patients with tumors ≤30 mm, more than 10 and 20 ELNs demonstrated the maximum OS difference during lobectomy and sublobectomy, respectively.</p><p><strong>Conclusions: </strong>This prognostic scoring system will anticipate the prognosis of stage I NSCLC patients after radical treatment, thereby offering individualized treatment recommendations for both clinicians and patients. A minimum of 10 ELNs during lobectomy and 20 ELNs during sublobectomy are necessary for small-sized NSCLC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"404-423"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 5-lncRNA signature predicts clinical prognosis and demonstrates a different mRNA expression in adult soft tissue sarcoma.","authors":"Ye Yao, Xiaojuan Wang, Ziwei Zhao, Zhipeng Li","doi":"10.21037/tcr-24-203","DOIUrl":"10.21037/tcr-24-203","url":null,"abstract":"<p><strong>Background: </strong>Adult soft tissue sarcoma (SARC) is a highly aggressive malignancy. A growing number of long non-coding RNAs (lncRNAs) have been linked to malignancies, and many researchers consider lncRNAs potential biomarkers for prognosis. However, there is limited evidence available to determine the role of lncRNAs in the prognosis of SARC. In this study, we collected The Cancer Genome Atlas (TCGA) data to identify prognosis-related lncRNAs for SARC and explore the relationship between lncRNAs and gene expression.</p><p><strong>Methods: </strong>TCGA datasets, which included 259 samples, served as data sources in this study. Univariable Cox regression analysis, robust analysis, and multivariable Cox regression analysis were used to construct a 5-lncRNA signature Cox regression model. Then, based on the median risk score, high- and low-risk groups were identified. The Kaplan-Meier method was applied to survival analysis in the training set, testing set, complete set, and different pathological type sets. To explore the relationship between lncRNAs and messenger RNAs (mRNAs), differentially expressed mRNAs (DEmRNAs) between the high- and low-risk groups were identified. The function of DEmRNAs was predicted using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The relationships between the 5 lncRNAs and DEmRNAs were calculated using the Spearman correlation coefficient. A total of 18 DEmRNAs that showed a strong correlation with risk score (|Spearman's r|>0.6) in leiomyosarcoma (LMS) samples were identified, and a protein-protein interaction (PPI) network was built using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database.</p><p><strong>Results: </strong>A Cox regression model was built in this study with the risk score= (-0.5698*<i>AC018645.2</i>) + 0.1732*<i>LINC02454</i> + 0.387*<i>ERICD</i> + 0.6262*<i>DSCR9</i> + 0.9781*<i>AL031770.1</i>. The study found that this 5-lncRNA signature could predict prognosis well, especially in LMS, a subtype of SARC, with P value =1.19e-06 [hazard ratio (HR) 6.134, 95% confidence interval (CI): 2.951-12.752]. Additionally, 44 DEmRNAs were observed between the high- and low-risk groups, and the expression levels of DEmRNAs in LMS samples differed from other pathology types. The PPI network analysis revealed that <i>MYH11</i>, <i>MYLK</i>, and <i>CNN1</i> were the most important hub genes among the 18 DEmRNAs, all of which are essential for muscle function.</p><p><strong>Conclusions: </strong>In this study, a predictive clinical model for SARC was successfully established, showing better prediction accuracy in patients with LMS. Importantly, we identified <i>MYH11</i>, <i>MYLK</i>, and <i>CNN1</i> as potential therapeutic targets for SARC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"179-196"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A diagnostic test of two-dimensional ultrasonic feature extraction based on artificial intelligence combined with blood flow Adler classification and contrast-enhanced ultrasound for predicting <i>HER-2</i>-positive breast cancer.","authors":"Kun Wang, Xi Yang, Shuo Yang, Xian Du, Ruijing Shi, Wendong Bai, Yu Wang","doi":"10.21037/tcr-24-2182","DOIUrl":"10.21037/tcr-24-2182","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Human epidermal growth factor receptor 2 (&lt;i&gt;HER-2&lt;/i&gt;) was an important driver gene for breast cancer which had high degree of malignancy and poor prognosis. Ultrasonography was an important imaging method for the diagnosis of breast cancer, but its diagnostic efficacy of &lt;i&gt;HER-2&lt;/i&gt;-positive breast cancer was not satisfactory. To assess the predictive value of two-dimensional ultrasonic feature extraction based on artificial intelligence (AI) combined with blood flow Adler classification and contrast-enhanced ultrasound (CEUS) for &lt;i&gt;HER-2&lt;/i&gt;-positive breast cancer, we compared the value of the area under the receiver operating characteristic (ROC) curve (AUC) of the combined diagnosis model and single-factor models.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was performed on 140 patients (88 &lt;i&gt;HER-2&lt;/i&gt;-positive and 52 &lt;i&gt;HER-2&lt;/i&gt;-negative). These patients were divided into internal test samples and external validation samples in a ratio of 7:3 randomly. The two samples were divided into &lt;i&gt;HER-2&lt;/i&gt;-positive group and &lt;i&gt;HER-2&lt;/i&gt;-negative group. All the patients were examined by two-dimensional ultrasound, color Doppler ultrasound, and CEUS, and AI was used to extract two-dimensional ultrasonic image features. Features of two-dimensional ultrasound included not parallel to the skin, irregular shape, unclear boundary, posterior echo attenuated, solid or cystic-solid mixed, microcalcification or coarse calcification were treated as &lt;i&gt;HER-2&lt;/i&gt;-positive. Levels of Doppler ultrasound included level 3 and level 4 were treated as &lt;i&gt;HER-2&lt;/i&gt;-positive. Features of CEUS included high enhancement, fast forward, centrifugal or diffuse, uneven, lesion range increased after CEUS, with perforating branches, unclear nodule boundary after CEUS were treated as &lt;i&gt;HER-2&lt;/i&gt;-positive. The ultrasonography characteristics in different ultrasonography methods were analyzed, the parameters with statistically significant differences between groups of internal test samples were incorporated to establish a joint diagnosis model. The sensitivity, specificity and accuracy of the combined diagnosis model and single-factor models were calculated, the ROC curve was drawn to evaluate the diagnostic efficacy of the combined diagnosis model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Long diameter direction, Adler grade of blood flow, contrast agent distribution characteristics, and nodule boundary after CEUS were statistically significant different between the positive and negative groups in internal test and external validation samples (P&lt;0.05). The sensitivity, specificity, accuracy of the combined diagnosis model were significantly higher than single-parameter diagnosis method both in internal test and external validation samples, and the kappa values of combined diagnosis model were highest. The AUC of the combined diagnosis model of internal test and external validation samples was 0.861 and 0.969, which was significantly highe","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"640-650"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A predictive nomogram for predicting liver metastasis in early-onset colon cancer: a population-based study.","authors":"Weichao Zeng, Yafeng Sun, Zhengrong Liao, Jianhua Xu","doi":"10.21037/tcr-24-1159","DOIUrl":"10.21037/tcr-24-1159","url":null,"abstract":"<p><strong>Background: </strong>The risk of liver metastasis (LM) may be estimated using predictive nomograms. While the nomogram has recently been applied in oncology, there are relatively few studies concentrating on predicting LM in patients with early-onset colon cancer. We aimed to identify independent risk factors for LM in patients with early-onset colon cancer and develop a nomogram for predicting the probability of LM in these patients.</p><p><strong>Methods: </strong>Our study encompassed 4,890 early-onset colon cancer patients with LM who were registered in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. These patients were randomly allocated into training and validation cohorts at a ratio of 7:3. Univariate and multivariate logistic regression analyses were conducted to identify the independent risk factors for LM, and a nomogram was developed using these factors. The model's discriminatory power, accuracy, and clinical utility were evaluated using receiver operating characteristics (ROC), calibration, and decision curve analyses.</p><p><strong>Results: </strong>Overall, 4,890 patients with early-onset colon cancer and LM were selected from the SEER database. LM incidence in these patients was 18.4%. Univariate and multivariate analyses revealed histological type, T stage, N stage, and carcinoembryonic antigen (CEA) level as independent risk factors. ROC curve analysis revealed that the predictive nomogram for LM risk had an area under the curve of 0.812 [95% confidence interval (CI): 0.795-0.829] and 0.809 (95% CI: 0.784-0.834) in the training and validation sets, respectively, demonstrating good discriminatory ability of the model. Calibration curve analysis showed good agreement between predicted values from the nomogram and actual observations, and the decision curve analysis (DCA) demonstrated the high clinical utility of the nomogram.</p><p><strong>Conclusions: </strong>LM incidence was higher in patients with early-onset colon cancer. Our nomogram demonstrates a high level of efficacy in predicting the risk of LM in patients with early-onset colon cancer, thereby assisting clinicians in making well-informed treatment decisions prior to further intervention.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"545-553"},"PeriodicalIF":1.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}